600713 南京医药
2026/09 - 九个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)5.7508.9128.5989.29311.232
总资产报酬率 ROA (%)1.1852.0121.9321.9242.071
投入资产回报率 ROIC (%)2.3003.5873.3413.7884.160

边际利润分析
销售毛利率 (%)6.1276.1546.2826.1836.490
营业利润率 (%)1.8502.1111.9061.8801.860
息税前利润/营业总收入 (%)2.6192.9462.8292.8232.671
净利润/营业总收入 (%)1.3071.5151.3841.3301.426

收益指标分析
经营活动净收益/利润总额(%)113.82489.973104.12596.540114.275
价值变动净收益/利润总额(%)0.6890.4390.4000.877-5.369
营业外收支净额/利润总额(%)-1.439-0.214-1.994-3.003-3.125

偿债能力分析
流动比率 (X)1.4421.5341.6271.4011.313
速动比率 (X)1.1431.1611.2591.0891.053
资产负债率 (%)77.34673.74274.61074.46478.848
带息债务/全部投入资本 (%)60.76252.95760.54955.94856.498
股东权益/带息债务 (%)60.47082.93461.10873.36471.618
股东权益/负债合计 (%)24.27131.00029.87930.41924.042
利息保障倍数 (X)3.2933.5072.9462.8293.082

营运能力分析
应收账款周转天数 (天)102.19181.40579.61987.57190.106
存货周转天数 (天)48.78746.02843.22341.47839.498